



SLOVENIAN SOCIETY OF CARDIOLOGY

endorsed by

EUROPEAN ACADEMY OF SCIENCES AND ARTS



Transcutaneous Contemporary Interventions-Valves

TCI-valves

where expertise merges experiences



Ljubljana

Ljubljana, Slovenia

April 10-11, 2024

ORGANISER

Slovenian Society of Cardiology,
Working Group on Invasive and Interventional Cardiology

ENDORSED BY

European Academy of Sciences and Arts

DATES

April 10 – 11, 2024

VENUE

Cankarjev dom, Prešernova c. 10, Ljubljana

COURSE DIRECTOR:

Matjaž Bunc

CO-DIRECTORS

Gian Paolo Ussia, Olaf Franzen, Ole De Backer, Joško Bulum,
Thomas Modine, Danny Dvir

SCIENTIFIC COMMITTEE

Matjaž Bunc, Gian Paolo Ussia, Olaf Franzen, Thomas Modine, Viktor
Kočka, Wojtek Wojakowski, Anton Farkaš, Joško Bulum, Joan Antoni
Gómez-Hospital, Zlatko Fras, Ole De Backer

ORGANISING COMMITTEE

Matjaž Bunc, Zlatko Fras, Miha Šušteršič, Klemen Steblovnik,
Luka Vitez, Peter Marko Mihailović, Miha Čerček, Simon Terseglav

INVITED INTERNATIONAL FACULTY

Ole De Backer, Danny Dvir, Gian Paolo Ussia, Olaf Franzen,
Thomas Modine, Viktor Kočka, Wojtek Wojakowski, Nicolas Brugger,
Tadeja Kolar, Matija Jelenc, Juš Kšela, Marta Cvijić, Mojca Bervar,
Jana Ambrožič, Ana Ovsenik, Tomaž Podlesnikar, Boštjan Berlot,
Joško Bulum, Siniša Dragnić, Igor Balevski, Vjekoslav Tomulić,
Krešimir Štambuk, Damir Kirner, Ivica Kristić, Saša Lukić, Saša Lončar,
Nina Glavnik, Irzal Hadžibegović, Klemen Steblovnik, Miha Čerček,
Joan Antoni Gómez-Hospital, Anton Farkaš

PROGRAM

DAY 1

Wednesday, April 10, 2024

9.00-11.30

MORNING 1

Kosovel Hall

PANELISTS:

Thomas Modine, Matjaž Bunc, Wojtek Wojakowski,
Gian Paolo Ussia

DISCUTANTS:

Viktor Kočka, Joško Bulum, Joan Antoni Gómez-
Hospital

9.00

Introduction

Matjaž Bunc

9.15

TAVI: contemporary approach

Wojtek Wojakowski

9.32

TAV and durability (explant..)

Thomas Modine

9.49

Low risk population clinical data

Wojtek Wojakowski

10.06

Optimal patient selection protocol (TAVI scores)

Gian Paolo Ussia

10.18

Planing

Viktor Kočka

10.30

PCI in TAVI candidates

Matjaž Bunc

10.42

Coronaty protection – when is it needed and how to do it?

Danny Dvir

10.54

VIV strategy: first implantation metters (small anatomy)

Joan Antoni Gómez-Hospital

DISCUSSION

Long term data VIV: TAVI in TAVI vs. TAV in SAVR

Danny Dvir

11.30-12.30

BREAK - COFFEE AND SNACKS

12.30-14.00

AFTERNOON 1

Kosovel Hall

FAST SHOOTING LECTURES

PANELISTS:

Wojtek Wojakowski, Thomas Modine,
Viktor Kočka, Gian Paolo Ussia

DISCUTANTS:

Joško Bulum, Krešimir Štambuk, Igor Balevski, Joan
Antoni Gómez-Hospital, Klemen Steblovnik

12.30

Calcified LVOT and ascending aorta

Wojtek Wojakowski

12.42

Bicuspid Ao

Klemen Steblovnik

12.54

LFLG AS

Viktor Kočka

13.06

TAVI in non-severe aortic stenosis

Krešimir Štambuk

13.18

TAV in small biovalve (BVF)

Irzal Hadžibegović

13.30

TAVI approaches and closure

Joško Bulum

13.42

TransCaval approach

Danny Dvir

PANEL DISCUSSION:

Optimization of TAVI today

14.00- 15.15

BREAK - LUNCH

15.15-17.00

AFTERNOON 2

Kosovel Hall

OPENING CEREMONY

Zlatko Fras

PANELISTS:

Gian Paolo Ussia, Wojtek Wojakowski,
Anton Farkaš, Thomas Modine

DISCUTANTS:

Matjaž Bunc, Joško Bulum, Ivica Kristić,
Vjekoslav Tomulić

15.30

Leaflet remodeling: clinical data

Gian Paolo Ussia

15.47

TMVR where are we now?

Thomas Modine

16.04

Other devices for mitral valve treatment

Thomas Modine

16.21

What are difficulties in percutaneous mitral valve treatment

Anton Farkaš

16.38

Case in the box. Comments

Wojtek Wojakowski

16.43

MAC: TAVI or Surgery or TMVR

Matjaž Bunc / Matija Jelenc

17.00-17.30

BREAK - COFFEE AND SNACKS

17.30-19.15

AFTERNOON 3

Kosovel Hall

PANELISTS:

Thomas Modine, Gian Paolo Ussia,
Wojtek Wojakowski, Matjaž Bunc

DISCUTANTS:

Anton Farkaš, Ivica Kristić, Miha Šušteršič,
Klemen Steblovnik

17.30

Clinical data for percutaneous tricuspid treatment

Anton Farkaš

17.47

Other devices for TC treatment

Thomas Modine

- 18.04** **What is not known/unanswered questions**
Gian Paolo Ussia
- 18.21** **RV hemodynamics and understanding RV-PA (un) coupling**
Marta Cvijić
- 18.38** **Multivalvular treatment: optimal approach**
Matjaž Bunc
- 18.55** **PANEL DISCUSSION**
How to select patients for TC percutaneous treatment
- 20.00** **DINNER**

DAY 2

Thursday, April 11, 2024

9.00-11.30

MORNING 1
Kosovel Hall

9.00

ACC after ACC 2024

Thomas Modine T. and Ole De Backer

9.30-9.35

BREAK

PANELISTS:

Ole De Backer, Viktor Kočka, Mojca Bervar, Boštjan Berlot, Nicolas Brugger

DISCUTANTS:

Jana Ambožič, Ana Ovsenik, Tomaž Podlesnikar

How to scan for select patients for transcatheter valvular procedures

9.35

Mitral-TEER

Jana Ambrožič

9.50

Tricuspid-TEER

Mojca Bervar

10.05

The role of CT and MRI

Boštjan Berlot

Tips and tricks in Echo guiding of mitral and tricuspid transcatheter procedures

10.20

Mitral valve procedures

Ana Ovsenik

10.35

Tricuspid valve procedures

Nicolas Brugger

10.50

TAVI and commissural alignment: importance and how to truly understand the aortic annulus S-curve

Ole De Backer

DISCUSSION

9.35-11.30

MORNING 1

E1 Conference Hall

PARALLEL SESSION

9.35

Tavi in low risk population: how to approach?

Ole De Backer

9.47

New devices on the horizon

Gian Paolo Ussia

TAVI FAST SHOOTING LECTURES

PANELISTS:

Gian Paolo Ussia, Danny Dvir, Ole De Backer, Viktor Kočka

DISCUTANTS:

Matjaž Bunc, Vjekoslav Tomulić, Igor Balevski

9.59

PM strategy

Damir Kirner

10.11

Brain protection

Vjekoslav Tomulić

10.23

Antithrombotic treatment

Siniša Dragnić

10.35

PCI in ACS after TAVI

Miha Čerček

10.47

How to approach to combined AS and MR?

Ivica Kristić

DISCUSSION

Which TAV device for which patient?

Matjaž Bunc

11.30-12.30

BREAK - COFFEE AND SNACKS

12.30-13.30	AFTERNOON 1 Kosovel Hall, E1 Conference Hall
	PARALLEL SESSION Young operators course and competition
	PANELISTS:
Group 1	KOSOVEL HALL: Gian Paolo Ussia, Igor Balevski, Krešimir Štambuk, Simon Terseglav, Ivica Kristić, Siniša Dragnić, Vjekoslav Tomulič
Group 2	E1 CONFERENCE HALL: Ole De Backer, Damir Kirner, Saša Lončar, Miha Čerček, Nina Glavnik, Viktor Kočka
Organising Committee:	Luka Vitez, Peter Marko Mihailović, Nina Glavnik, Klemen Steblovnik
	TOPICS: (2 GROUPS COMPETITION)
	Closure devices Optimal valve selection How to handle complications Tamponade Hypotension Acute Pv leak Valve displacement
13.30-14.30	BREAK - LUNCH

14.30-16.00	AFTERNOON 2 Kosovel Hall
	SATELLITE SYMPOSIA
16.00-17.00	AFTERNOON 3 Kosovel Hall
	PANELISTS: Viktor Kočka, Gian Paolo Ussia, Matjaž Bunc, Krešimir Štambuk, Siniša Dragnić, Ivica Kristić
	BEST 3 CASES AWARDS
	PANEL DISCUSSION Future perspectives
17.00	CLOSURE OF MEETING

14.30-16.00

AFTERNOON 2

Kosovel Hall

SATELLITE SYMPOSIA

Structural tools and clinical applications

PANELISTS:

Ole De Backer, Thomas Modine, Matjaž Bunc,
Gian Paolo Ussia, Vjekoslav Tomulić

14.30

AR challenge and it's solution

Ole De Backer (sponsored by JenaValve Technology)

14.40

Clinical advancements in Abbott Structural Heart therapies

Marie Ollivry-Wautot (sponsored by Abbott)

14.50

Medtronic's pipeline

- What's coming in 2024 & beyond

Bojana Stoimenov (sponsored by Medtronic)

15.00

Novel advances in TAVI

Milos Medrick (sponsored by Edwards)

15.10

Structural heart product pipeline

Anders Jonsson (sponsored by Biosensors)

15.20

Kaleidoscope of Structural Heart Devices in Meril's pipeline

Vjekoslav Tomulić (sponsored by Meril)

15.30

Boston Scientific Structural Heart Valves Portfolio

Konstantinos Foteinos (sponsored by Boston Scientific)

15.40

Tricvalve


- the device to treat Right Heart Failure!

Katharina Kiss (sponsored by Medical Intertrade)

SYMEDRIX

INNOWI SX - TAVI WIRE

0.035 Inch / 0,89mm
270 cm



3-Zone-Technology

The TAVI wire has three independent zones of stiffness providing optimal support:

- The ultra-stiff proximal portion of the wire facilitates easy advancing of the introducer sheath
- The super-stiff portion adapts perfectly to the anatomy in the aortic arch and provides sufficient guidance and support for the valve introducer system
- The Pig-Tail-Tip allows atraumatic positioning in the ventricle, thereby protecting the heart muscle during the implantation of the valve

 **BORMIAMED**
Think Care Innovate



ALLEGRA is a trademark or registered trademark of NVT AG. ALLEGRA™ is CE approved (CE 0124). Third party brands are trademarks of their respective intellectual property right owners.
 CAUTION: The law restricts these devices to sale by or on the order of a physician and these products are intended for the use by or under the direction of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Not available in the United States and any other country where applicable health authority product registration has not been obtained. Information contained herein only for presentation outside the US and France. ALLEGRA™ is a product of NVT AG, manufactured at its affiliated company NVT GmbH.
 Blue Sail Medical Co., Ltd is the parent company of NVT AG and Biosensors International Group, Ltd. and its affiliates are collaborating for the commercialization of the ALLEGRA™ device. © 2024 NVT AG. All rights reserved.

Built for now and what's next



Choose the Edwards SAPIEN 3 Ultra as your strategy for success in lifetime management



See what makes the SAPIEN 3 platform the ideal choice for lifetime management at [heartvalves.com](https://www.edwards.com/heartvalves.com)

1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. *N Engl J Med.* 2019;380(18):1695-1705.
2. Williams MR, Jilaihawi H, Makkar R, et al. The PARTNER 3 Bicuspid Registry for transcatheter aortic valve replacement in low-surgical-risk patients. *JACC Cardiovasc Interv.* 2022;15(5):523-532.
3. Nazif T, Daniels D, McCabe J, et al. Real-world experience with the SAPIEN 3 Ultra TAVI: A propensity matched analysis from the United States. Presented virtually at: TVT Connect 2020; June 18-28, 2020.
4. Makkar RR, et al. Outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves: a registry study. *Lancet.* 2023 Oct 28;402(10412):1529-1540.
5. Mack MJ, et al. Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years. *N Engl J Med.* 2023 Oct 24. doi:10.1056/NEJMoa2307447. Epub ahead of print.
6. Tarantini G, Nai Fovino L, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. *Circ Cardiovasc Interv.* 2020;13(7):3008972.
7. Data on file. Edwards Lifesciences Corporation. 2022.
8. Kazerooni NA, Tkatchouk E. Porcine vs bovine pericardium assessment as leaflet in aortic valves. Presented at: Heart Valve Society (HVS) 2022; March 2-5, 2022; Miami, FL.
9. Nazif TM, Cahill TJ, Daniels D, et al. Real-world experience with the SAPIEN 3 Ultra transcatheter heart valve: a propensity-matched analysis from the United States. *Cir Cardiovasc Interv.* 2021;14(9):e010543.
10. De Backer O, Landes U, Fuchs A, et al. Coronary access after TAVR-in-TAVR as evaluated by multidetector computed tomography. *JACC Cardiovasc Interv.* 2020;13(21):2528-2538. doi:10.1016/j.jcin.2020.06.016.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult [eifu.edwards.com](https://www.edwards.com) where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, PARTNER, PARTNER II, PARTNER 3, SAPIEN, SAPIEN 3, and SAPIEN 3 Ultra are trademarks and service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2024 Edwards Lifesciences Corporation. All rights reserved. PP-EU-6845 v2.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • [edwards.com](https://www.edwards.com)



Edwards

IMPLANTING TAVI



ACURATE neo2™
Aortic Valve System



SENTINEL™
Cerebral Protection System



iSLEEVE™
Expandable Introducer




SAFARI2™
Pre-Shaped Guidewire

All trademarks are property of their respective owner. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

**EVOLUT™ PRO+
TAVI SYSTEM
NOW CE MARKED**



EXPECT
MORE



Actor portrayal

**THE EVOLUT™ PRO+
TAVI SYSTEM
ADVANTAGE**

From a design built on a proven platform[†], the Evolut™ PRO+ system provides the performance and outcomes you need to help patients live life to the fullest.



**HEMODYNAMIC
PERFORMANCE**

for exceptional patient outcomes²



**ADVANCED
SEALING**

for all valve sizes and across the broadest self-expanding annular range[†]



**LOW DELIVERY
PROFILE**

for access down to 5.0 mm vessels with the 23-29 mm valves

References:

[†] Broadest annulus range based on CT derived diameters for self-expanding valves

1. Data on file (>20 clinical trials with over 20,000 patients enrolled).

2. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.

See the CoreValve™ Evolut™ R, the CoreValve™ Evolut™ PRO and the Evolut™ PRO+ device manuals for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

For applicable products, consult instructions for use on manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat™ Reader with the browser.

The commercial name of the Evolut™ R device is Medtronic CoreValve™ Evolut™ R System, the commercial name of the Evolut™ PRO device is Medtronic CoreValve™ Evolut™ PRO System, and the commercial name of the Evolut™ PRO+ device is Medtronic Evolut™ PRO+ System.

NAVITOR™ TAVI SYSTEM

RIGHT VALVE. RIGHT TIME.

FOR TODAY, TOMORROW,
AND THE ROAD AHEAD.

1 TODAY

Easy, calm, and stable deployment.

DELIVERABILITY

EASE OF USE

2 TOMORROW

Excellent hemodynamics.

SINGLE-DIGIT GRADIENTS¹

MINIMAL PROSTHESIS-PATIENT MISMATCH²


EXCELLENT PVL MITIGATION¹

3 THE ROAD AHEAD

Uncompromised coronary access for future procedures.

CORONARY ACCESS

LOWEST NEOSKIRT HEIGHT^{3*}



DISCOVER WHAT
HEART VALVE
EXPERTS THINK

SCAN QR CODE TO LEARN MORE

*Among commercially available self-expanding TAVI valves.

REFERENCES: 1. Smith D. One-year clinical trial results with a next-generation aortic transcatheter heart valve. Presented at: EuroPCR conference, May 17-20, 2022. 2. Sultan I. Hemodynamic outcomes and prosthesis-patient mismatch of the Navitor valve. Presented at: TVT 2022, June 8-10, 2022. 3. Akodad M, Sellers S, Gulcin GS, et al. Leaflet and neoskirt height in transcatheter heart valves: implications for repeat procedures and coronary access. JACC Cardiovasc Interv. 2021;14(20):2298-2300. doi:10.1016/j.jcin.2021.07.034.

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use inside the product carton (when available) or at efu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions, and Adverse Events. Information contained herein for DISTRIBUTION in Europe, Middle East and Africa ONLY. Always check the regulatory status for the device in your region. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

Abbott Vascular International BVBA
Park Lane, Culliganlaan 2B, 1831 Diegem, Belgium, Tel: 32.2.714.14.11
™ indicates a trademark of the Abbott Group of Companies.
www.structuralheart.abbott

©2023 Abbott. All rights reserved. 9-EH-2-13917-01-01-2023



MitraClip™
Transcatheter Edge-to-Edge Repair

PUSHING THE BOUNDARIES IN MR REDUCTION¹



91%
WITH MR ≤1+
Highest MR
reduction in TEER^{*}



5 YEARS
DURABILITY^{**}
Longest durability
in TEER to date



35 MINS
DEVICE TIME
Shortest device
time to date



4 CLIP SIZES
AVAILABLE
Tailored repair for complex
& non-complex anatomies



MORE THAN **150.000** LIVES CHANGED

REFERENCES

1. Von Bardeleben R.S., Contemporary Clinical and Echocardiographic Outcomes of 1000+ Patients Treated with MitraClip(TM) G4: Results from the EXPAND G4 Post Approval Study. Data Presented at TCT 2022.
^{*}MR reduction at 30 days. ^{**}EVEREST II Family of trials, Final Report on file.

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at vascular.efu.abbott or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Information contained herein for DISTRIBUTION in Europe, Middle East Africa ONLY. Data on file at Abbott. Always check the regulatory status of the device in your region. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

Abbott Vascular International BVBA
Park Lane, Culliganlaan 2B, 1831 Diegem, Belgium, Tel: 32.2.714.14.11
™ indicates a trademark of the Abbott Group of Companies.
www.structuralheart.abbott

©2022 Abbott. All rights reserved. 9-EH-2-13776-0111-2022



Myval

OCTACOR

TRANSCATHETER HEART VALVE



CARDIO MEDICAL



Edwards



More to Life

